Literature DB >> 6721995

Rifampicin kinetics in undernutrition.

K Polasa, K J Murthy, K Krishnaswamy.   

Abstract

Rifampicin 10 mg/kg was administered as a single dose to eight undernourished subjects, 10 well nourished subjects and 10 undernourished patients on continuous antituberculosis therapy as a single dose. The area under plasma time concentration (AUC0----infinity) and the peak concentration were significantly reduced in both the undernourished groups. The apparent oral and renal clearances were increased in both the undernourished groups. The (AUC0----infinity) was reduced in undernourished due to reduced absorption and/or changes in total body clearance or disposition. The plasma protein binding of the drug was significantly reduced in the undernourished resulting in increased free drug concentration. This might be sufficient to ensure adequate therapeutic efficacy. Therefore alteration in dosage regimes are not necessary in the undernourished.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721995      PMCID: PMC1463407          DOI: 10.1111/j.1365-2125.1984.tb02377.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

Review 1.  Drug metabolism and pharmacokinetics in malutrition.

Authors:  K Krishnaswamy
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

Review 2.  Nutrition and drug-metabolizing enzymes.

Authors:  T C Campbell
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

3.  A survey of diabetes mellitus in a rural population of India.

Authors:  K S Rao; N R Mukherjee; K V Rao
Journal:  Diabetes       Date:  1972-12       Impact factor: 9.461

4.  Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week.

Authors:  G Acocella; R Mattiussi; G Segre
Journal:  Pharmacol Res Commun       Date:  1978-03

5.  Optimized determination of gamma-glutamyltransferase by reaction-rate analysis.

Authors:  S B Rosalki; D Tarlow
Journal:  Clin Chem       Date:  1974-09       Impact factor: 8.327

6.  [Renal clearance of rifampicin].

Authors:  F Reubi; W Sackmann; L Plünnecke
Journal:  J Urol Nephrol (Paris)       Date:  1970-09

7.  Investigation on the serum and lung tissue level of rifampicin in man.

Authors:  I J Kiss; E Faragó; I Juház; S Bacsa; E Fábián
Journal:  Int J Clin Pharmacol Biopharm       Date:  1976-01

Review 8.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

  8 in total
  16 in total

1.  Protein Binding of First-Line Antituberculosis Drugs.

Authors:  Wael A Alghamdi; Mohammad H Al-Shaer; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Grand rounds--Hammersmith Hospital. Persistent fever in pulmonary tuberculosis.

Authors:  M T Barakat; J Scott; J M Hughes; M Walport; J Calam; J S Friedland; P W Ind; C McKenna
Journal:  BMJ       Date:  1996-12-14

3.  Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.

Authors:  Roger K Verbeeck; Bonifasius S Singu; Dan Kibuule
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

4.  Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Authors:  Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.

Authors:  Alma Tostmann; Charles M Mtabho; Hadija H Semvua; Jossy van den Boogaard; Gibson S Kibiki; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

6.  Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.

Authors:  Helen McIlleron; Roxana Rustomjee; Mahnaz Vahedi; Thuli Mthiyane; Paolo Denti; Catherine Connolly; Wasima Rida; Alexander Pym; Peter J Smith; Philip C Onyebujoh
Journal:  Antimicrob Agents Chemother       Date:  2012-03-12       Impact factor: 5.191

7.  Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.

Authors:  L H M te Brake; R Ruslami; H Later-Nijland; F Mooren; M Teulen; L Apriani; J B Koenderink; F G Russel; D M Burger; B Alisjahbana; F Wieringa; R van Crevel; R E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

8.  Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

Authors:  Luis F López-Cortés; Rosa Ruiz-Valderas; Pompeyo Viciana; Aristides Alarcón-González; Jesús Gómez-Mateos; Eva León-Jimenez; Maria Sarasanacenta; Yolanda López-Pua; Jerónimo Pachón
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Influences of diet and nutrition on clinical pharmacokinetics.

Authors:  K E Anderson
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

Review 10.  Drug metabolism and pharmacokinetics in malnourished children.

Authors:  K Krishnaswamy
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.